Concepedia

Matthew T. Campbell

MT

Statistics

Publications

85

Citations

7.7K

H-Index

32

Active since

1993

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Institut Gustave Roussy

Cleveland Clinic

Matthew T. Campbell is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer immunotherapy.

ORCID

Publications per year

1993–2025

85

Publications

85

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

, , +6

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Yinghong Wang, Diana H. Wiesnoski, Beth A. Helmink et al. · Nature Medicine · 2018 · 721 citations

, , +14

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer, Paul B. Robbins, Thomas Powles et al. · Nature Medicine · 2020 · 522 citations · Full text

, , +15

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Toni K. Choueiri, Robert J. Motzer, Brian I. Rini et al. · Annals of Oncology · 2020 · 461 citations · Full text

, , +15

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Jianjun Gao, Neema Navai, Omar Alhalabi et al. · Nature Medicine · 2020 · 313 citations · Full text

, , +14

1–5 of 85